CALT - Callidatas stock jumps 15% after FDA grants full approval for Tarpeyo
2023-12-21 11:11:40 ET
More on Calliditas Therapeutics
- Calliditas Therapeutics: Undervalued Rare Disease Commercial Stage Biotech (Maintaining Buy)
- Calliditas partner wins China nod for kidney disease therapy
- Calliditas stock dips as losses widen in Q3
- Seeking Alpha’s Quant Rating on Calliditas Therapeutics
- Historical earnings data for Calliditas Therapeutics
For further details see:
Callidatas stock jumps 15% after FDA grants full approval for Tarpeyo